ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1046
0,00%
Bitcoin
67.276,37
0,50%
Brent Oil
83,76
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Revance Therapeutics Inc (RVNC)

  7. Revance Therapeutics Inc (RVNC) Notícias

RVNC

Revance Therapeutics (RVNC)

Revance Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RVNC
DataHoraFonteTítuloCódigoCompanhia
09/05/202417:33Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RVNCRevance Therapeutics Inc
09/05/202417:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVNCRevance Therapeutics Inc
09/05/202417:06Business WireRevance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
09/05/202417:05Business WireRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaNASDAQ:RVNCRevance Therapeutics Inc
02/05/202417:05Business WireRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:RVNCRevance Therapeutics Inc
12/04/202409:00Business WireRevance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingNASDAQ:RVNCRevance Therapeutics Inc
27/03/202417:05Business WireRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RVNCRevance Therapeutics Inc
08/03/202418:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
05/03/202419:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RVNCRevance Therapeutics Inc
04/03/202411:25Business WireRevance Announces Pricing of $100.0 Million Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
04/03/202408:37Business WireRevance Announces Proposed Public Offering of Common StockNASDAQ:RVNCRevance Therapeutics Inc
29/02/202418:36Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RVNCRevance Therapeutics Inc
28/02/202418:05Business WireRevance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
21/02/202410:01Business WireRevance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024NASDAQ:RVNCRevance Therapeutics Inc
21/02/202410:00Business WireRevance to Participate in Upcoming Investor ConferencesNASDAQ:RVNCRevance Therapeutics Inc
14/02/202417:45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
02/02/202410:00Business WireRevance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®NASDAQ:RVNCRevance Therapeutics Inc
01/02/202410:00Business WireRevance to Participate in the Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:RVNCRevance Therapeutics Inc
11/01/202408:18IH Market NewsWall Street Highlights: Mastercard’s Financial Rise, Citigroup’s $3.8 Billion Charges, and MoreNASDAQ:RVNCRevance Therapeutics Inc
08/01/202410:00Business WireRevance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial OutlookNASDAQ:RVNCRevance Therapeutics Inc
12/12/202307:50IH Market NewsHasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and MoreNASDAQ:RVNCRevance Therapeutics Inc
14/11/202318:22Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RVNCRevance Therapeutics Inc
08/11/202318:06Business WireRevance Reports Third Quarter 2023 Financial Results, Provides Corporate UpdateNASDAQ:RVNCRevance Therapeutics Inc
08/11/202318:05Business WireRevance Appoints Erica Jordan as Chief Commercial Officer, AestheticsNASDAQ:RVNCRevance Therapeutics Inc
01/11/202309:00Business WireRevance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023NASDAQ:RVNCRevance Therapeutics Inc
26/10/202309:00Business WireDAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best InventionsNASDAQ:RVNCRevance Therapeutics Inc
24/10/202317:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:RVNCRevance Therapeutics Inc
19/09/202310:00Business WireRevance Provides Corporate Update at Investor DayNASDAQ:RVNCRevance Therapeutics Inc
06/09/202317:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RVNCRevance Therapeutics Inc
01/09/202310:12Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:RVNCRevance Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RVNC

Seu Histórico Recente

USOTC
FITX
Creative Edge Nutrition (CE)
ASX
AHR
Anchor Resources
NASDAQ
UNUM
BIT
I08950
Intesa Sanpaolo
LSE
DO14
Citi Fun 25
NYSE
RLTY
Cohen & Steers Real Esta...
POLO
ESDUSDT
Empty Set Dollar
NASDAQ
USCTU
Roth CH Acquisition
EU
FR001400KX37
Ginkgo personal loans Gi...
BOV
PLAS3
PLASCAR PART ON
BOV
CORR4
COR RIBEIRO PN
BIT
UB261U
UniCredit Bank
AMEX
UAG
E TRACS UBS Bloomberg CM...
BOV
AURE3
Auren Energia ON
NASDAQ
AAZYYXX
Bank of Montreal Atm Dig...
USOTC
CLRYF
Clarocity (CE)
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados